Clinical experience with lanreotide for the treatment of acromegaly

Expert Review of Endocrinology and Metabolism

Volumn 7, Issue 2, 2012, Pages 139-149

  Roemmler, Josefine ^a   Schopohl, Jochen ^a  

^a UNIVERSITY OF MUNICH   (Germany)

Author keywords

acromegaly; depot medication; GH; lanreotide; somatostatin analogues

Indexed keywords

ANGIOPEPTIN; CABERGOLINE; CHOLECYSTOKININ; GASTRIC INHIBITORY POLYPEPTIDE; INTRAVAIL; MOTILIN; OCTREOTIDE; PANCREAS POLYPEPTIDE; PASIREOTIDE; PEGVISOMANT; PLACEBO; SOMATOSTATIN; SOMATOSTATIN RECEPTOR 2; SOMATOSTATIN RECEPTOR 5; UNCLASSIFIED DRUG;

ACROMEGALY; ANEMIA; ARTHRALGIA; ARTICLE; BRADYCARDIA; CANCER PATIENT; CELL PROLIFERATION; CHOLELITHIASIS; CONSTIPATION; DIARRHEA; DRUG HALF LIFE; ENZYME BLOOD LEVEL; FLATULENCE; GALLSTONE; GLUCOSE INTOLERANCE; GROWTH HORMONE BLOOD LEVEL; GROWTH HORMONE SECRETING ADENOMA; HEADACHE; HUMAN; HYPERTENSION; INJECTION SITE MASS; INJECTION SITE REACTION; INSULIN RELEASE; LOOSE FECES; MULTICENTER STUDY (TOPIC); NAUSEA; NEUROENDOCRINE TUMOR; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; SIDE EFFECT; SINGLE DRUG DOSE; THYROTROPIN SECRETING ADENOMA; TUMOR CELL; TUMOR GROWTH; VOMITING;

EID: 84858063698     PISSN: 17446651     EISSN: 17448417     Source Type: Journal    
DOI: 10.1586/eem.11.93     Document Type: Article

References (77)

1. Holdaway IM, Rajasoorya C. Epidemiology of acromegaly. Pituitary 2(1), 29-41 (1999).
2. Melmed S. Acromegaly pathogenesis and treatment. J. Clin. Invest. 119(11), 3189-3202 (2009).
3. .Schneider HJ, Sievers C, Saller B, Wittchen HU, Stalla GK. High prevalence of biochemical acromegaly in primary care patients with elevated IGF-1 levels. Clin. Endocrinol. (Oxf). 69(3), 432-435 (2008).
4. Dekkers OM, Biermasz NR, Pereira AM, Romijn JA, Vandenbroucke JP. Mortality in acromegaly: a meta-analysis. J. Clin. Endocrinol. Metab. 93(1), 61-67 (2008).
5. Holdaway IM, Bolland MJ, Gamble GD. A meta-analysis of the effect of lowering serum levels of GH and IGF-I on mortality in acromegaly. Eur. J. Endocrinol. 159(2), 89-95 (2008).
6. Giustina A, Chanson P, Bronstein MD et al. A consensus on criteria for cure of acromegaly. J. Clin. Endocrinol. Metab. 95(7), 3141-3148 (2010).
7. Weber MM. Akromegalie. In: Erkrankungen von Hypothalamus und Hypophyse. Jockenhövel F, Gerhards G (Eds). Petersenn Unimed, Bremen, Germany, 111-121 (2011).
8. Melmed S, Casanueva F, Cavagnini F et al. Consensus statement: medical management of acromegaly. Eur. J. Endocrinol. 153(6), 737-740 (2005).
9. Gonzalez B, Vargas G, Espinosa-de-los- Monteros AL, Sosa E, Mercado M. Efficacy and safety of radiotherapy in acromegaly. Arch. Med. Res. 42(1), 48-52 (2011).
10. Attanasio R, Epaminonda P, Motti E et al. Gamma-knife radiosurgery in acromegaly: a 4-year follow-up study. J. Clin. Endocrinol. Metab. 88(7), 3105-3112 (2003).
11. Abs R, Verhelst J, Maiter D et al. Cabergoline in the treatment of acromegaly: a study in 64 patients. J. Clin. Endocrinol. Metab. 83(2), 374-378 (1998).
12. Sandret L, Maison P, Chanson P. Place of cabergoline in acromegaly: a meta-analysis. J. Clin. Endocrinol. Metab. 96(5), 1327-1335 (2011).
13. Freda PU. Somatostatin analogs in acromegaly. J. Clin. Endocrinol. Metab. 87(7), 3013-3018 (2002).
14. Colao A, Auriemma RS, Rebora A et al. Significant tumour shrinkage after 12 months of lanreotide Autogel-120 mg treatment given first-line in acromegaly. Clin. Endocrinol. (Oxf.) 71(2), 237-245 (2009).
15. Mazziotti G, Giustina A. Effects of lanreotide SR and Autogel on tumor mass in patients with acromegaly: a systematic review. Pituitary 13(1), 60-67 (2010).
16. Petersenn S, Schopohl J, Barkan A et al. Pasireotide (SOM230) demonstrates efficacy and safety in patients with acromegaly: a randomized, multicenter, Phase II trial. J. Clin. Endocrinol. Metab. 95(6), 2781-2789 (2010).
17. Neggers SJ, de Herder WW, Feelders RA, van der Lely AJ. Conversion of daily pegvisomant to weekly pegvisomant combined with long-acting somatostatin analogs, in controlled acromegaly patients. Pituitary 14(3), 253-258 (2011).
18. Neggers SJ, de Herder WW, Janssen JA, Feelders RA, van der Lely AJ. Combined treatment for acromegaly with long-acting somatostatin analogs and pegvisomant: long-term safety for up to 4.5 years (median 2.2 years) of follow-up in 86 patients. Eur. J. Endocrinol. 160(4), 529-533 (2009).
19. Neggers SJ, van Aken MO, Janssen JA, Feelders RA, de Herder WW, van der Lely AJ. Long-term efficacy and safety of combined treatment of somatostatin analogs and pegvisomant in acromegaly. J. Clin. Endocrinol. Metab. 92(12), 4598-4601 (2007).
20. Neggers SJ, van der Lely AJ. Combination treatment with somatostatin analogues and pegvisomant in acromegaly. Growth Horm. IGF Res. 21(3), 129-133 (2011).
21. van der Lely AJ, Bernabeu I, Cap J et al. Coadministration of lanreotide Autogel and pegvisomant normalizes IGF1 levels and is well tolerated in patients with acromegaly partially controlled by somatostatin analogs alone. Eur. J. Endocrinol. 164(3), 325-333 (2011).
22. Trainer PJ, Drake WM, Katznelson L et al. Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. N. Engl. J. Med. 342(16), 1171-1177 (2000).
23. van der Lely AJ, Hutson RK, Trainer PJ et al. Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. Lancet 358(9295), 1754-1759 (2001).
24. Schreiber I, Buchfelder M, Droste M et al. Treatment of acromegaly with the GH receptor antagonist pegvisomant in clinical practice: safety and efficacy evaluation from the German Pegvisomant Observational Study. Eur. J. Endocrinol. 156(1), 75-82 (2007).
25. Buhk JH, Jung S, Psychogios MN et al. Tumor volume of growth hormonesecreting pituitary adenomas during treatment with pegvisomant: a prospective multicenter study. J. Clin. Endocrinol. Metab. 95(2), 552-558 (2010).
26. Jaquet P, Gunz G, Saveanu A et al. Efficacy of chimeric molecules directed towards multiple somatostatin and dopamine receptors on inhibition of GH and prolactin secretion from GH-secreting pituitary adenomas classified as partially responsive to somatostatin analog therapy. Eur. J. Endocrinol. 153(1), 135-141 (2005).
27. Saveanu A, Lavaque E, Gunz G et al. Demonstration of enhanced potency of a chimeric somatostatin-dopamine molecule, BIM-23A387, in suppressing growth hormone and prolactin secretion from human pituitary somatotroph adenoma cells. J. Clin. Endocrinol. Metab. 87(12), 5545-5552 (2002).
28. Ciccarelli A, Daly A, Beckers A. Lanreotide Autogel® for acromegaly: a new addition to the treatment armamentarium. Treat. Endocrinol. 3(2), 77-81 (2004).
29. Bevan JS, Newell-Price J, Wass JA et al. Home administration of lanreotide Autogel by patients with acromegaly, or their partners, is safe and effective. Clin. Endocrinol. (Oxf.) 68(3), 343-349 (2008).
30. Salvatori R, Nachtigall LB, Cook DM et al. Effectiveness of self or partner administration of an extended-release aqueous-gel formulation of lanreotide in lanreotide-naive patients with acromegaly. Pituitary 13(2), 115-122 (2010).
31. Adelman DT, Burgess A, Davies PR. Nurse evaluation of long-acting somatostatin analogue injection devices: a quantitative study. Presented at: 8th Annual ENETS Conference. Lisbon, Portugal, 9-11 March 2011.
32. Hu M, Tomlinson B. Pharmacokinetic evaluation of lanreotide. Expert Opin Drug Metab. Toxicol. 6(10), 1301-1312 (2010).
33. Valery C, Paternostre M, Robert B et al. Biomimetic organization: octapeptide self-assembly into nanotubes of viral capsid-like dimension. Proc. Natl Acad. Sci USA 100(18), 10258-10262 (2003).
34. de Herder WW, Lamberts SW. Somatostatin and somatostatin analogues: diagnostic and therapeutic uses. Curr. Opin. Oncol. 14(1), 53-57 (2002).
35. Paniagua AE, Bernabeu I, Leskela S, Marazuela M. Lanreotide autogel-induced tumour shrinkage in thyrotropin-secreting pituitary macroadenomas. Clin. Endocrinol. (Oxf.) 74(3), 406-408 (2011).
36. Appetecchia M, Baldelli R. Somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine tumours, current aspects and new perspectives. J. Exp. Clin. Cancer Res. 29, 19 (2010).
37. Croxtall JD, Scott LJ. Lanreotide Autogel: a review of its use in the management of acromegaly. Drugs 68(5), 711-723 (2008).
38. Steffin B, Gutt B, Bidlingmaier M, Dieterle C, Oltmann F, Schopohl J. Effects of the long-acting somatostatin analogue Lanreotide Autogel on glucose tolerance and insulin resistance in acromegaly. Eur. J. Endocrinol. 155(1), 73-78 (2006).
39. Gutt B, Bidlingmaier M, Kretschmar K, Dieterle C, Steffin B, Schopohl J. Four-year follow-up of acromegalic patients treated with the new long-acting formulation of Lanreotide (Lanreotide Autogel). Exp. Clin. Endocrinol. Diabetes 113(3), 139-144 (2005).
40. Molitch ME. Lanreotide Autogel in the management of acromegaly. Drugs 68(5), 724 (2008).
41. Kuhn JM, Legrand A, Ruiz JM, Obach R, De Ronzan J, Thomas F. Pharmacokinetic and pharmacodynamic properties of a long-acting formulation of the new somatostatin analogue, lanreotide, in normal healthy volunteers. Br. J. Clin. Pharmacol. 38(3), 213-219 (1994).
42. Heron I, Thomas F, Dero M et al. Pharmacokinetics and efficacy of a long-acting formulation of the new somatostatin analog BIM 23014 in patients with acromegaly. J. Clin. Endocrinol. Metab. 76(3), 721-727 (1993).
43. Somatuline® Depot (lanreotide) injection, prescribing information. Ipsen Pharma, Paris, France (2011).
44. Antonijoan RM, Barbanoj MJ, Cordero JA et al. Pharmacokinetics of a new Autogel formulation of the somatostatin analogue lanreotide after a single subcutaneous dose in healthy volunteers. J. Pharm. Pharmacol. 56(4), 471-476 (2004).
45. Cendros JM, Peraire C, Troconiz IF, Obach R. Pharmacokinetics and population pharmacodynamic analysis of lanreotide Autogel. Metabolism 54(10), 1276-1281 (2005).
46. Murray RD, Melmed S. A critical analysis of clinically available somatostatin analog formulations for therapy of acromegaly. J. Clin. Endocrinol. Metab. 93(8), 2957-2968 (2008).
47. Bronstein M, Musolino N, Jallad R et al. Pharmacokinetic profile of lanreotide Autogel in patients with acromegaly after four deep subcutaneous injections of 60, 90 or 120 mg every 28 days. Clin. Endocrinol. (Oxf) 63(5), 514-519 (2005).
48. Troconiz IF, Cendros JM, Peraire C et al. Population pharmacokinetic analysis of lanreotide Autogel in healthy subjects: evidence for injection interval of up to 2 months. Clin. Pharmacokinet. 48(1), 51-62 (2009).
49. Garrido MJ, Cendros JM, Ramis J, Peraire C, Obach R, Troconiz IF. Pharmacodynamic modeling of the effects of lanreotide autogel on growth hormone and insulin-like growth factor 1. J. Clin. Pharmacol. doi:10.1177/ 0091270011399761 (2011) (Epub ahead of print).
50. Castinetti F, Saveanu A, Morange I, Brue T. Lanreotide for the treatment of acromegaly. Adv. Ther. 26(6), 600-612 (2009).
51. Melmed S, Cook D, Schopohl J, Goth MI, Lam KS, Marek J. Rapid and sustained reduction of serum growth hormone and insulin-like growth factor-1 in patients with acromegaly receiving lanreotide Autogel therapy: a randomized, placebocontrolled, multicenter study with a 52 week open extension. Pituitary 13(1), 18-28 (2010).
52. Toledano Y, Rot L, Greenman Y et al. Efficacy of long-term lanreotide treatment in patients with acromegaly. Pituitary 12(4), 285-293 (2009).
53. Caron P, Cogne M, Raingeard I, Bex- Bachellerie V, Kuhn JM. Effectiveness and tolerability of 3-year lanreotide Autogel treatment in patients with acromegaly. Clin. Endocrinol. (Oxf.) 64(2), 209-214 (2006).
54. Colao A, Auriemma RS, Galdiero M, Lombardi G, Pivonello R. Effects of initial therapy for five years with somatostatin analogs for acromegaly on growth hormone and insulin-like growth factor-I levels, tumor shrinkage, and cardiovascular disease: a prospective study. J. Clin. Endocrinol. Metab. 94(10), 3746-3756 (2009).
55. Andries M, Glintborg D, Kvistborg A, Hagen C, Andersen M. A 12-month randomized crossover study on the effects of lanreotide Autogel and octreotide long-acting repeatable on GH and IGF-l in patients with acromegaly. Clin. Endocrinol. (Oxf.) 68(3), 473-480 (2008).
56. Kelly P, Maher KT, Chew SL, Monson JP, Grossman AB, Jenkins PJ. A single-center open-label study to investigate the efficacy and safety of repeated subcutaneous injections of lanreotide Autogel in patients with acromegaly previously treated with octreotide. Endocr. Pract. 16(2), 191-197 (2010).
57. Ronchi CL, Boschetti M, Degli Uberti EC et al. Efficacy of a slow-release formulation of lanreotide (Autogel) 120 mg) in patients with acromegaly previously treated with octreotide long acting release (LAR): an open, multicentre longitudinal study. Clin. Endocrinol. (Oxf.) 67(4), 512-519 (2007).
58. Schopohl J, Strasburger CJ, Caird D et al. Efficacy and acceptability of lanreotide Autogel® 120 mg at different dose intervals in patients with acromegaly previously treated with octreotide LAR. Exp. Clin. Endocrinol. Diabetes 119(3), 156-162 (2011).
59. Chanson P, Borson-Chazot F, Kuhn JM, Blumberg J, Maisonobe P, Delemer B. Control of IGF-I levels with titrated dosing of lanreotide Autogel over 48 weeks in patients with acromegaly. Clin. Endocrinol. (Oxf.) 69(2), 299-305 (2008).
60. Lombardi G, Minuto F, Tamburrano G et al. Efficacy of the new long-acting formulation of lanreotide (lanreotide Autogel) in somatostatin analogue-naive patients with acromegaly. J. Endocrinol. Invest. 32(3), 202-209 (2009).
61. Maiza JC, Vezzosi D, Matta M et al. Long-term (up to 18 years) effects on GH/ IGF-1 hypersecretion and tumour size of primary somatostatin analogue (SSTa) therapy in patients with GH-secreting pituitary adenoma responsive to SSTa. Clin. Endocrinol. (Oxf.) 67(2), 282-289 (2007).
62. Lucas T, Astorga R, Catala M. Preoperative lanreotide treatment for GH-secreting pituitary adenomas: effect on tumour volume and predictive factors of significant tumour shrinkage. Clin. Endocrinol. (Oxf.) 58(4), 471-481 (2003).
63. Mao ZG, Zhu YH, Tang HL et al. Preoperative lanreotide treatment in acromegalic patients with macroadenomas increases short-term postoperative cure rates: a prospective, randomised trial. Eur. J. Endocrinol. 162(4), 661-666 (2010
64. Attanasio R, Lanzi R, Losa M et al. Effects of lanreotide Autogel on growth hormone, insulinlike growth factor 1, and tumor size in acromegaly: a 1-year prospective multicenter study. Endocr. Pract. 14(7), 846-855 (2008)
65. Bevan JS. Clinical review: the antitumoral effects of somatostatin analog therapy in acromegaly. J. Clin. Endocrinol. Metab. 90(3), 1856-1863 (2005).
66. Melmed S, Sternberg R, Cook D et al. A critical analysis of pituitary tumor shrinkage during primary medical therapy in acromegaly. J. Clin. Endocrinol. Metab. 90(7), 4405-4410 (2005)
67. Zatelli MC, Piccin D, Ambrosio MR, Bondanelli M, degli Uberti EC. Antiproliferative effects of somatostatin analogs in pituitary adenomas. Pituitary 9(1), 27-34 (2006).
68. Cozzi R, Attanasio R, Lodrini S, Lasio G. Cabergoline addition to depot somatostatin analogues in resistant acromegalic patients: efficacy and lack of predictive value of prolactin status. Clin. Endocrinol. (Oxf.) 61(2), 209-215 (2004).
69. Selvarajah D, Webster J, Ross R, Newell- Price J. Effectiveness of adding dopamine agonist therapy to long-acting somatostatin analogues in the management of acromegaly. Eur. J. Endocrinol. 152(4), 569-574 (2005).
70. Marzullo P, Ferone D, Di Somma C et al. Efficacy of combined treatment with lanreotide and cabergoline in selected therapy-resistant acromegalic patients. Pituitary 1(2), 115-120 (1999).
71. Lucas T, Astorga R. Efficacy of lanreotide Autogel administered every 4-8 weeks in patients with acromegaly previously responsive to lanreotide microparticles 30 mg: a Phase III trial. Clin. Endocrinol. (Oxf) 65(3), 320-326 (2006).
72. Abrams P, Alexopoulou O, Abs R, Maiter D, Verhelst J. Optimalization and cost management of lanreotide-Autogel therapy in acromegaly. Eur. J. Endocrinol. 157(5), 571-577 (2007).
73. Alexopoulou O, Abrams P, Verhelst J et al. Efficacy and tolerability of lanreotide Autogel therapy in acromegalic patients previously treated with octreotide LAR. Eur. J. Endocrinol. 151(3), 317-324 (2004).
74. Mazziotti G, Floriani I, Bonadonna S, Torri V, Chanson P, Giustina A. Effects of somatostatin analogs on glucose homeostasis: a metaanalysis of acromegaly studies. J. Clin. Endocrinol. Metab. 94(5), 1500-1508 (2009).
75. Maggio EE, Grasso P. Oral delivery of octreotide acetate, a synthetic analog of somatostatin, in Intravail®, improves uptake, serum half-life, and bioavailability over subcutaneous injection: a pharmacokinetic study in male Swiss Webster mice. Regul. Pept. 167(2-3), 233-238 (2011).
76. Chieffo C, Ryan M, Malott C, Frohman LA. Pharmacodynamics and safety of an 84-mg subcutaneous octreotide hydrogel implant for the treatment of acromegaly. Presented at: The Annual Meeting of the Endocrine Society. Boston, MA, USA, 4-7 June 2011 (Abstract).
77. Chieffo C, Ryan M, Malott C, Gadelha MR, Frohman LA. Rates of biochemical response in patients with acromegaly treated with a subcutaneous octreotide hydrogel implant. Presented at: The Annual Meeting of the Endocrine Society. Boston, MA, USA, 4-7 June 2011 (Abstract).